Getinge today announces that, during the second quarter of 2026, the company received a tariff refund of approximately USD 36 M, corresponding to the majority of the tariffs paid under the International Emergency Economic Powers Act (IEEPA). In total, the tariffs previously paid by Getinge under IEEPA amount to approximately USD 38 M.
Since the tariffs were introduced in April 2025, Getinge has continuously included information in its financial reporting on the amount paid by the company each quarter. Following the U.S. Supreme Court's ruling in February 2026 that IEEPA does not authorize the imposition of tariffs, and subsequent decisions by the U.S. Court of International Trade regarding refunds to importers, U.S. Customs and Border Protection has established a dedicated refund process.
Getinge has applied for a refund under this process and, during the end of the second quarter of 2026, received approximately USD 36 M of the tariffs previously paid.
As a result of the refund, Getinge will recognize a positive non-recurring effect in the second quarter of 2026 through a reduction in cost of goods sold of approximately USD 38 M, allocated across the respective business areas. To provide a fair view of performance over the 2025-2026 period, Getinge applies the same accounting principle to the refund as to the original tariff costs. The refund will therefore not be reported as an item affecting comparability (IAC), since the previous tariff costs were not reported as items affecting comparability (IAC).
Getinge continues to adhere to applicable tariff regulations and pays the import duties required for the company's operations.
The interim report for the second quarter of 2026 will be published on July 17, 2026, at 08.00 a.m. CEST.
Contact information
David Kördel, Head of Investor Relations
Phone: +46(0)10 335 0077
E-mail: david.kordel@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.